Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub
Nuwellis Receives FDA Clearance For An Additional Dual Lumen Extended Length Peripheral Catheter
Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its
AMA’s Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here’s What To Expect
The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply.
T2 Biosystems Announces FDA 510(k) Submission To Expand Use Of The FDA-Cleared T2Candida Panel To Include Pediatric Testing
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food
Intensity Therapeutics Announced A Business Update Reflecting Progress In Its Phase 3 Sarcoma Clinical Program; FDA Provided “Study May Proceed Letter” For Phase 3 Within 30 Day Period Following IND Submission
IND Submission for Phase 3In the fourth quarter of 2023, the Company submitted a new Investigational New Drug ("IND") to the Food and Drug Administration ("FDA"). The submission included the phase 3 protocol for a
Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy
Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly ad
Why Is Neurology Focused Cingulate Stock Trading Higher Today?
On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance f
NeuroBo Pharmaceuticals Submits IND Application To The FDA For A Phase 1 Clinical Trial Of DA-1726 For The Treatment Of Obesity
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to
Why Coherus BioSciences Stock Is Climbing Today
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Wednesday after the company announced the FDA approval of its pegfilgrastim delivery device, Udenyca Onbody.
FDA Slaps Clinical Hold On Iovance Biotherapeutics’ Lung Cancer Study After Patient Death
Wednesday, Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced a clinical program update for LN-145 TIL therapy in non-